Skip to content

The Effect of Manipulation of the Cervical Spine on Pain Biomarkers

The Effect of High-Velocity Low-Amplitude Thrust Manipulation of the Cervical Spine on Pain Biomarkers in Females With Non-Specific Mechanical Neck Pain

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03176654
Acronym
HVLAT
Enrollment
28
Registered
2017-06-05
Start date
2016-08-15
Completion date
2016-09-20
Last updated
2019-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neck Pain, Posterior

Brief summary

This study evaluates the effect of high-velocity low-amplitude thrust (HVLAT) manipulation to the cervical spine on neuropeptide expression as determined by the plasma concentration of oxytocin, neurotensin, orexin A and cortisol; and Examine the effect of HVLAT manipulation on pain perception in symptomatic females with non-specific mechanical cervical spine pain

Detailed description

A high-velocity low-amplitude thrust (HVLAT) manipulation or commonly known as a spinal manipulation, is an intervention frequently used by physical therapists and other healthcare practitioners as an alternative treatment to help relieve spinal pain The mechanism by which HVLAT manipulation modulates pain remains undefined, although this does not contradict the clinical effects from HVLAT manipulation. Furthermore, there is evidence that suggests analgesia after HVLAT manipulation. There is a variety of observed and proposed phenomena that can explain the mechanisms for the psychological, mechanical, or neurophysiological responses from a HVLAT manipulation associated with alterations in pain processing or sympathetic and motor systems' excitation.

Interventions

HVLAT will be performed 10 minutes after the first blood draw.

PROCEDURESham HVLAT manipulation

Sham HVLAT will be performed 10 minutes after the first blood draw.

Sponsors

Loma Linda University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)

Intervention model description

Experimental Group (HVLAT manipulation) Control Group (sham HVLAT manipulation)

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* 20 - 45 years of age * A score of 10 or more out of 50 on the Neck Disability Index (NDI) questionnaire * Symptoms of pain present for 30 days or less and no pain symptoms below your shoulder

Exclusion criteria

* Serious condition (such as cancer, spondylolisthesis, rheumatoid arthritis, or ankylosing spondylitis) * Cervical spinal stenosis signs (such as incoordination in hands, arms and legs, inability of walking at a brisk pace, or bowel and bladder incontinence) * Nerve root compression (such as changes in sensation, muscle weakness, or decreased reflexes) * Works the night shift * Steroid medication within 3 months * Pregnancy or postpartum * Pending legal action regarding their neck pain * History of whiplash associated disorder and/or cervical spine surgery

Design outcomes

Primary

MeasureTime frameDescription
Plasma Concentration of OxytocinBlood will be drawn 10 minutes prior to HVLAT procedure.Samples were analyzed for Human Oxytocin, using the Multiplex Luminex-100 platform (Luminex, Inc., USA).

Secondary

MeasureTime frameDescription
Plasma Concentration of NeurotensinWithin 10 minutes after consent signature completionSamples were analyzed for Human Neurotensin, using the Multiplex Luminex-100 platform (Luminex, Inc., USA).
Plasma Concentration of Orexin AWithin 10 minutes after consent signature completionSamples were analyzed for Human Orexin A, using the Multiplex Luminex-100 platform (Luminex, Inc., USA).
Plasma Concentration of CortisolWithin 10 minutes after consent signature completionSamples were analyzed for Human Cortisol, using the Multiplex Luminex-100 platform (Luminex, Inc., USA).

Countries

United States

Participant flow

Participants by arm

ArmCount
HVLAT Manipulation
An HVLAT manipulation is applied to the site of pain or restriction with the patient in supine. This technique uses both primary levers (pre-manipulation rotation - away (30 ° - 45 °) from the side of pain or limitation) and secondary levers (Side bending - towards coupled with lateral shift - away, and posterior-anterior (PA) shift (extension). This is a bimanual technique. For the applicator hand, the anterolateral portion of the first or second phalanx of the second ray was positioned on the superior joint partner of the target vertebrae using a cradle hold. The other hand is placed on the posterolateral aspect of the occiput (above the ear). While maintaining these positions the clinician performed the thrust with the arc of rotation dependent on the level of the target vertebrae. HVLAT manipulation: HVLAT will be performed 10 minutes after the first blood draw.
13
Sham HVLAT Manipulation
Subjects in the control group were instructed to lay on a table in the same position as the HVLAT manipulation group. The clinician went through the same basic steps as the HVLAT manipulation, localizing the appropriate vertebral landmarks but without carrying out the final HVLA thrust procedure. Sham HVLAT manipulation: Sham HVLAT will be performed 10 minutes after the first blood draw.
15
Total28

Baseline characteristics

CharacteristicSham HVLAT ManipulationTotalHVLAT Manipulation
Age, Customized
Mean age of participants
30 years37 years37 years
Race and Ethnicity Not Collected0 Participants
Sex/Gender, Customized15 Participants28 Participants13 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 130 / 15
other
Total, other adverse events
0 / 130 / 15
serious
Total, serious adverse events
0 / 130 / 15

Outcome results

Primary

Plasma Concentration of Oxytocin

Samples were analyzed for Human Oxytocin, using the Multiplex Luminex-100 platform (Luminex, Inc., USA).

Time frame: Blood will be drawn 10 minutes prior to HVLAT procedure.

Population: Twenty-eight female subjects with non-specific mechanical neck pain randomly assigned to one of two interventions (HVLAT or Sham HVLAT).

ArmMeasureValue (MEAN)Dispersion
HVLAT ManipulationPlasma Concentration of Oxytocin154.5 ug/mlStandard Deviation 0.9
Sham HVLAT ManipulationPlasma Concentration of Oxytocin158.8 ug/mlStandard Deviation 0.5
Primary

Plasma Concentration of Oxytocin

Samples were analyzed for Human Oxytocin, using the Multiplex Luminex-100 platform (Luminex, Inc., USA).

Time frame: Blood will be drawn immediately after HVLAT procedure.

Population: Twenty-eight female subjects with non-specific mechanical neck pain randomly assigned to one of two interventions (HVLAT or Sham HVLAT).

ArmMeasureValue (MEAN)Dispersion
HVLAT ManipulationPlasma Concentration of Oxytocin185.1 ug/mlStandard Deviation 0.9
Sham HVLAT ManipulationPlasma Concentration of Oxytocin189.1 ug/mlStandard Deviation 0.5
Secondary

Plasma Concentration of Cortisol

Samples were analyzed for Human Cortisol, using the Multiplex Luminex-100 platform (Luminex, Inc., USA).

Time frame: Blood will be drawn immediately after HVLAT procedure.

Population: Twenty-eight female subjects with non-specific mechanical neck pain randomly assigned to one of two interventions (HVLAT or Sham HVLAT).

ArmMeasureValue (MEAN)Dispersion
HVLAT ManipulationPlasma Concentration of Cortisol108.1 ug/mlStandard Deviation 0.8
Sham HVLAT ManipulationPlasma Concentration of Cortisol139.7 ug/mlStandard Deviation 0.5
Secondary

Plasma Concentration of Cortisol

Samples were analyzed for Human Cortisol, using the Multiplex Luminex-100 platform (Luminex, Inc., USA).

Time frame: Within 10 minutes after consent signature completion

Population: Twenty-eight female subjects with non-specific mechanical neck pain randomly assigned to one of two interventions (HVLAT or Sham HVLAT).

ArmMeasureValue (MEAN)Dispersion
HVLAT ManipulationPlasma Concentration of Cortisol95.8 ug/mlStandard Deviation 0.8
Sham HVLAT ManipulationPlasma Concentration of Cortisol127.4 ug/mlStandard Deviation 0.5
Secondary

Plasma Concentration of Neurotensin

Samples were analyzed for Human Neurotensin, using the Multiplex Luminex-100 platform (Luminex, Inc., USA).

Time frame: Within 10 minutes after consent signature completion

Population: Twenty-eight female subjects with non-specific mechanical neck pain randomly assigned to one of two interventions (HVLAT or Sham HVLAT).

ArmMeasureValue (MEAN)Dispersion
HVLAT ManipulationPlasma Concentration of Neurotensin116.0 ug/mlStandard Deviation 1.6
Sham HVLAT ManipulationPlasma Concentration of Neurotensin125.6 ug/mlStandard Deviation 0.2
Secondary

Plasma Concentration of Neurotensin

Samples were analyzed for Human Neurotensin, using the Multiplex Luminex-100 platform (Luminex, Inc., USA).

Time frame: Blood will be drawn immediately after HVLAT procedure.

Population: Twenty-eight female subjects with non-specific mechanical neck pain randomly assigned to one of two interventions (HVLAT or Sham HVLAT).

ArmMeasureValue (MEAN)Dispersion
HVLAT ManipulationPlasma Concentration of Neurotensin136.4 ug/mlStandard Deviation 1.6
Sham HVLAT ManipulationPlasma Concentration of Neurotensin131.6 ug/mlStandard Deviation 0.2
Secondary

Plasma Concentration of Orexin A

Samples were analyzed for Human Orexin A, using the Multiplex Luminex-100 platform (Luminex, Inc., USA).

Time frame: Within 10 minutes after consent signature completion

Population: Twenty-eight female subjects with non-specific mechanical neck pain randomly assigned to one of two interventions (HVLAT or Sham HVLAT).

ArmMeasureValue (MEAN)Dispersion
HVLAT ManipulationPlasma Concentration of Orexin A52.2 ug/mlStandard Deviation 1
Sham HVLAT ManipulationPlasma Concentration of Orexin A62.9 ug/mlStandard Deviation 0.2
Secondary

Plasma Concentration of Orexin A

Samples were analyzed for Human Orexin A, using the Multiplex Luminex-100 platform (Luminex, Inc., USA).

Time frame: Blood will be drawn immediately after HVLAT procedure.

Population: Twenty-eight female subjects with non-specific mechanical neck pain randomly assigned to one of two interventions (HVLAT or Sham HVLAT).

ArmMeasureValue (MEAN)Dispersion
HVLAT ManipulationPlasma Concentration of Orexin A73.8 ug/mlStandard Deviation 1
Sham HVLAT ManipulationPlasma Concentration of Orexin A67.3 ug/mlStandard Deviation 0.2

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026